Summit Therapeutics (SMMT) Tops Q4 EPS by 1c

Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.07), GBP0.01 better than the analyst estimate of (GBP0.08).

For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.

You May Also Be Interested In

• Nelson Peltz Prepares Bid For Wendy’s - FT
• UBS Upgrades Multi Commodity Exchange of India Ltd (MCX:IN) to Buy
• NetEase (NTES) call put ratio 1.5 calls to 1 put into quarter results